June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Inhibition of TGFβ2-induced ocular hypertension using CRISPR interference
Author Affiliations & Notes
  • Naga pradeep Rayana
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Weiming Mao
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Chenna Kesavulu Sugali
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Jiannong Dai
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Footnotes
    Commercial Relationships   Naga pradeep Rayana, None; Weiming Mao, None; Chenna Sugali, None; Jiannong Dai, None
  • Footnotes
    Support  BrightFocus Foundation G2017151 (W.M.)
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 479. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Naga pradeep Rayana, Weiming Mao, Chenna Kesavulu Sugali, Jiannong Dai; Inhibition of TGFβ2-induced ocular hypertension using CRISPR interference. Invest. Ophthalmol. Vis. Sci. 2021;62(8):479.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Studies have shown that elevated TGFβ2 induces pathological changes in the trabecular meshwork (TM) leading to ocular hypertension (OHT) which are similar to the phenotypes observed in primary open-angle glaucoma. Our published studies suggest that elevated TGFβ2 may be due to promoter region hyperacetylation in the TM. dCAS9 is a mutated form of CAS9, the key enzyme in the CRISPR system. When fused with KRAB, a repression domain, and guided by sgRNA, dCAS9-KRAB can repress gene expression without altering genomic DNA (CRISPR interference). In this study, we showed that CRISPR interference is a useful tool in decreasing intraocular pressure (IOP) by repressing TGFβ2 in mouse eyes.

Methods : Lentiviral dCAS9-KRAB and sgRNA expression vectors were co-transduced into TM cells at an MOI value of 1 to 50. On the fifth day post-transduction, cell lysate and condition medium were extracted and the expression of TGFβ2 and dCAS9 were determined using western immunoblotting. Lentiviral CRISPR interference vectors or control vectors were injected into mouse eyes followed by a second injection of adenoviral vectors expression active TGFβ2.

Results : Our initial screening showed two guide RNAs from a pool of sgRNAs were able to decrease the expression of TGFβ2 compared to control sgRNA in GTM3 cells. We also found similar efficiency of the sgRNAs in the inhibition of TGFβ2 in primary TM cell strains. ChIP-qPCR showed enrichment of dCAS9-KRAB at the TGFβ2 promoter region. In addition to TM cells, we tested our system in a mouse model. We injected male (n=6) and female (n=6) mouse eyes with lentiviral vectors expressing dCAS9-KRAB together with sgRNA targeting the CMV promoter or non-targeting sgRNA as control. We then injected both eyes with Ad5-CMV-ΔhTGFβ2. We found that specific sgRNA expressing eyes did not develop OHT while control sgRNA expressing eyes developed OHT (p<0.05).

Conclusions : CRISPR interference can be used as an important tool in decreasing TGFβ2 and TGFβ2-induced OHT. It can be used as an alternative for siRNA.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×